Neurocrine Biosciences Inc.

(NBIX) Trade

By |

Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Contact Information

Website: www.neurocrine.com
Email: ir@neurocrine.com
Main Phone: +1 858 617-7600
Address: 12780 El Camino Real
State: CA
City / Town: San Diego
Country: US
Postal Code: 92130

Issuer Information

Exchange: NGS
CEO: Kevin C. Gorman
Employees: 780
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More

Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Contact Information

Website: www.neurocrine.com
Email: ir@neurocrine.com
Main Phone: +1 858 617-7600
Address: 12780 El Camino Real
State: CA
City / Town: San Diego
Country: US
Postal Code: 92130

Issuer Information

Exchange: NGS
CEO: Kevin C. Gorman
Employees: 780
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More
$ 100.94 $ 1.93 (1.95%)
Last Price 100.94 Change $ 1.93 Change % 1.95 Tick N/A
Bid 95.19 Bid Size 100.00 Ask 101.20 Ask Size 100.00
Open 98.01 High 101.18 Low 97.84 Prev Close 99.01
Last Trade Volume 737,312 52 Wk Hi 136.27 52 Wk Low 72.14
Market Cap 9.4 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 93,254,872.00 EPS (TTM) 2.12 PE Ratio 46.70 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 13 103
Number of Buys 5 35
Number of Sells 8 68
Net Activity 27377 -27712
Last 10 Buys Shares
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
W. Thomas Mitchell 1,000
Last 10 Sell Shares
Stephen A. Sherwin 1,000
Eric S. Benevich 1,000
Corinne H. Nevinny 1,000
Kevin C. Gorman 1,000
Darin Lippoldt 1,000
Kyle Gano 1,000
Haig P. Bozigian 1,000
Haig P. Bozigian 1,000
Gary A. Lyons 1,000
Dimitri E. Grigoriadis 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 139 139 139 139
Low Target Price Estimate 85 85 85 85
Mean Target Price Estimate 106 106 106.33 106
Standard Deviation 13.86 13.86 13.99 13.86
Date of Most Recent Estimate 05/29/18 05/29/18 05/14/18 05/29/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 10 10 11 11
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.09 1.09 1.08 1.08